Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company based in Houston that develops fibroblast-based therapies and fibroblast-derived materials for chronic diseases. These regulatory documents offer detailed information on the company’s capital structure, governance, financing arrangements, and stockholder proposals.
FibroBiologics’ filings include Forms 8-K describing material events such as securities purchase agreements, registered direct offerings, concurrent private placement warrants, use of sovereign-issued gold coins as consideration in one offering, and the payoff of convertible promissory notes issued under a Standby Equity Purchase Agreement. Other 8-K filings disclose Nasdaq notices related to minimum bid price and Market Value of Listed Securities requirements, along with the company’s potential options to address these listing standards.
The company’s proxy statements on Schedule 14A outline items submitted to stockholders, including a proposed reverse stock split within a specified ratio range, approvals for issuances of common stock underlying various warrant agreements under Nasdaq Listing Rule 5635(d), and an adjournment proposal. These documents also discuss voting rights, such as the Series C Preferred Stock with super voting rights and the irrevocable proxy in favor of the board of directors.
Through this page, users can review FibroBiologics’ annual and quarterly reports when available, current reports on Form 8-K, and proxy materials, with AI-powered tools that summarize key terms, highlight financing structures, and clarify complex provisions. Investors can also use the filings to understand warrant terms, reverse split authorizations, Nasdaq compliance disclosures, and other regulatory details that shape the risk and capital profile of FBLG.
FibroBiologics (FBLG) filed its Q3 2025 report showing higher expenses and a wider loss, alongside a going concern warning. For the quarter ended September 30, 2025, operating expenses rose to $5.0 million, driven by research and development of $2.8 million and general and administrative of $2.2 million. The company reported a net loss of $5.8 million for the quarter and $15.4 million for the nine months.
Cash and cash equivalents were $4.9 million, down from $14.0 million at year-end, with net cash used in operations of $13.2 million year-to-date. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company detailed its Standby Equity Purchase Agreement, under which it issued $15.0 million in short-term convertible notes in three tranches and may require the investor to purchase up to an additional $10.0 million of common stock, subject to conditions. During 2025, $9.7 million of notes converted into 13,059,270 shares; additional conversions occurred in October. Shares outstanding were 48,263,979 as of September 30, 2025, and 51,456,077 as of October 31, 2025.
FibroBiologics, Inc. received a notification from the Nasdaq Listing Qualifications Staff that it does not meet the Nasdaq Capital Market requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35.0 million. The notice does not immediately affect the trading of the company’s common stock, but gives the company a 180-calendar-day cure period to regain compliance by having MVLS close at $35.0 million or more for at least ten consecutive business days before February 2, 2026. If the company fails to regain compliance, Nasdaq will notify FibroBiologics that its securities are subject to delisting, and the company may seek an appeal, though there is no assurance an appeal would be granted. The company stated it will monitor MVLS and consider options to regain compliance and filed this report to publicly disclose receipt of the Nasdaq notice.